|
GSK Resumes Sales of Paxil CR; Cidra Plant Cleared of Problems
GlaxoSmithKline (GSK) has resumed U.S. sales of Paxil CR — a move that comes roughly four months after the firm voluntarily halted production of the antidepressant because of quality concerns. This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives